EMA Weighs Easing Clinical Trial Demands to Speed Testing of Hemophilia Therapies
The European Medicines Agency (EMA) is considering lowering the minimum number of patients required in clinical trials of potential hemophilia treatments…
Articles by Margarida Azevedo, MSc
New Data on Hemophilia Drug Candidate Emicizumab Presented by Genentech at 2016 World Congress
Genentech recently presented positive Phase 1/2 extension results for its investigational hemophilia A medicine, emicizumab, at the 2016Â World Federation…
Bruising ‘Uncommon’ in Very Young Children with Blood Disorders, Study Reports
Researchers analyzed the patterns of bruising in children younger than six years old to understand the extent to which their…
FDA Approves Easier Preparation System for Hemophilia A Patients on Adynovate Therapy
Shire recently announced that the U.S. Food and Drug Administration (FDA) has approved its Baxject III reconstitution system for Adynovate, an approved treatment…
Clinical Data of Gene Therapy AMT-060 for Severe Hemophilia B Updated
uniQure N.V. has updated the clinical data from its ongoing clinical trial of a gene therapy for the treatment of…
Gene Therapy for Severe Hemophilia A, BMN 270, Showing Early Promise in Clinical Trial
BioMarin Pharmaceuticals presented positive interim data from an open-label Phase 1/2 clinical trial of BMN 270, an investigational gene therapy for severe…
6 Hemophilia Researchers and Doctors in US Awarded Grants by Bayer
Bayer announced that six hemophilia clinicians and researchers in the United States were among 16 grant recipients under the company’s Hemophilia…
FDA Grants Breakthrough Designation for Hemophilia B Treatment
The US Food and Drug Administration has granted Breakthrough Therapy Designation to biotech Spark Therapeutics and pharmacology giant Pfizer for…
Biogen and Sobi to Present Long-term Data on Hemophilia A and B Therapies at WFH 2016
Biogen and Sobi announced that they will be presenting updated and long-term data on two approved hemophilia treatments, Eloctate  (marketed as…
CSL to Present New Data on 2 Hemophilia Treatments, Idelvion and Afstyla, at the WFH Congress
CSL Behring announced that new data from studies of two approved treatments for hemophilia — Idelvion and Afstyla, both recombinant coagulation factors…